Tenet Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Strong demand for high-acuity care and disciplined capital deployment support robust growth projections. AI and automation drive efficiency, while commercial rates remain favorable and ambulatory expansion continues. Capital priorities include service line investment, share buybacks, and debt reduction.
-
An accretive $2.65 billion asset sale of Conifer's contract with CommonSpirit strengthens cash flow, returns full strategic control, and enables accelerated investment in automation, AI, and offshoring. Capital allocation priorities remain focused on share repurchases and USPI growth.
Fiscal Year 2025
-
2025 saw strong revenue and margin growth, with Adjusted EBITDA up 14% and robust free cash flow. 2026 guidance anticipates continued growth, though headwinds from expiring tax credits are expected. Capital deployment remains focused on M&A, share repurchases, and technology-driven efficiencies.
-
Q3 2025 saw strong revenue and EBITDA growth, margin expansion, and robust free cash flow, prompting raised full-year guidance for revenue, EBITDA, and capital expenditures. USPI and hospital segments both delivered solid performance, with continued M&A activity and disciplined cost controls supporting future growth.
-
Earnings and free cash flow guidance were raised, driven by strong core performance and margin expansion. Policy focus is on extending premium tax credits and Medicaid payments, while capital investment is increasing in high-acuity and ambulatory growth. Operational efficiency and cost control remain priorities.
-
Q2 2025 saw 19% adjusted EBITDA growth and margin expansion, with strong USPI and hospital performance. Full-year guidance was raised for revenue, EBITDA, and free cash flow, supported by high-acuity strategies and robust payer mix.
-
Strong growth in high-acuity ambulatory procedures and disciplined capital deployment are driving revenue and margin improvements. Policy uncertainty is managed through long-term payer contracts and operational focus, while labor and competition remain stable.
-
First quarter 2025 saw strong revenue and EBITDA growth, margin expansion, and robust performance across both ambulatory and hospital segments, driven by higher acuity, favorable payer mix, and disciplined cost management. Guidance for the full year remains unchanged, with continued focus on M&A, capital investments, and share repurchases.
-
Medicaid and ACA policy remain politically sensitive, with strong resistance to cuts and continued advocacy for subsidies. Strategic focus is on high-acuity, high-margin services, especially in ASCs, with robust financial performance, disciplined capital deployment, and strong growth in orthopedics and total joint procedures.
Fiscal Year 2024
-
2024 saw robust revenue and EBITDA growth, margin expansion, and significant portfolio transformation, including hospital divestitures and ASC expansion. 2025 guidance projects continued growth, strong cash flow, and active capital deployment, with regulatory risks managed through operational discipline.
-
Multi-year operational improvements and strategic divestitures have strengthened margins, reduced leverage, and positioned the business for growth. Strong demand, especially in ambulatory surgery, and disciplined capital allocation support a positive outlook into 2025.
-
Q3 2024 results exceeded expectations with strong volume growth, higher margins, and robust free cash flow. Full-year guidance was raised, reflecting continued operational outperformance and portfolio transformation, while deleveraging and capital returns remain key priorities.
-
The organization has achieved significant deleveraging and portfolio optimization, enabling increased investment in high-growth areas like ambulatory services and acute care hospitals. Strong operational discipline, robust demand, and strategic ASC expansion underpin positive financial outlooks, while exchange and Medicaid dynamics remain key focus areas.
-
Q2 2024 results exceeded expectations with 12% Adjusted EBITDA growth and strong margins across segments. Full-year guidance was raised for revenue, EBITDA, and free cash flow, supported by robust demand, cost control, and capital deployment, including a new $1.5B share repurchase program.